Socio-Economic Value of Adult Immunisation Programmes

Adult vaccines can return up to 19 times their initial investment to society, when their significant benefits beyond the healthcare system are monetised. This report demonstrates the health and socioeconomic value of adult immunisation programmes against seasonal influenza (influenza), pneumococcal disease (PD), herpes zoster (HZ), and respiratory syncytial virus (RSV) in ten countries (Australia, Brazil, France, Germany, Italy, Japan, Poland, South Africa, Thailand, and the United States of America).